Fig. 2.

Forest plot showing A empagliflozin users had significantly lower risk of death compared to dapagliflozin users among DM population B Sotagliflozin users had a lower risk of cardiovascular death and HHF in HF patients C Canagliflozin users had significantly lower risk of cardiovascular death and HHF in non-HF patients D Sotagliflozin users had a significant lower risk of MACE than placebo users, but other SGLT2 inhibitors didn’t for HF population E Less selective SGLT2 inhibitors(canagliflozin and sotagliflozin) users had significant lower risk of MACE compared with highly selective SGLT-2 inhibitors(dapagliflozin, empagliflozin, and ertugliflozin) users for HF patients. AKI acute kidney injury, DM Diabetes Mellitus, HF Heart failure, HHF hospitalization heart failure, MACE Major adverse cardiac events, SGLT2 Sodium–Glucose Cotransporter 2